

# ACR–SABI–SAR–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) OF THE LIVER

The American College of Radiology, with more than 40,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

## PREAMBLE

This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care<sup>1</sup>. For these reasons and those set forth below, the American College of Radiology and our collaborating medical specialty societies caution against the use of these documents in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the practitioner considering all the circumstances presented. Thus, an approach that differs from the guidance in this document, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by variables such as the condition of the patient, limitations of available resources, or advances in knowledge or technology after publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document may consider documenting in the patient record information sufficient to explain the approach taken.

The practice of medicine involves the science, and the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The purpose of this document is to assist practitioners in achieving this objective.

---

<sup>1</sup> *Iowa Medical Society and Iowa Society of Anesthesiologists v. Iowa Board of Nursing*, 831 N.W.2d 826 (Iowa 2013) Iowa Supreme Court refuses to find that the "ACR Technical Standard for Management of the Use of Radiation in Fluoroscopic Procedures (Revised 2008)" sets a national standard for who may perform fluoroscopic procedures in light of the standard's stated purpose that ACR standards are educational tools and not intended to establish a legal standard of care. See also, *Stanley v. McCarver*, 63 P.3d 1076 (Ariz. App. 2003) where in a concurring opinion the Court stated that "published standards or guidelines of specialty medical organizations are useful in determining the duty owed or the standard of care applicable in a given situation" even though ACR standards themselves do not establish the standard of care.

## I. INTRODUCTION

This practice parameter was developed and written collaboratively by the American College of Radiology (ACR), the Society for Advanced Body Imaging (SABI), the Society of Abdominal Radiology (SAR), and the Society of Pediatric Radiology (SPR).

Magnetic resonance imaging (MRI) of the liver is a proven and useful tool for the evaluation, assessment of severity, and follow-up of diseases of the liver. Although liver MRI is one of the most sensitive diagnostic tests for

detection and characterization of hepatic lesions, findings may be misleading if not closely correlated with the results of previous imaging studies, clinical history, physical examination, or laboratory tests. Adherence to the following parameters will enhance the probability of accurately assessing such abnormalities.

## **II. INDICATIONS**

Indications for MRI of the liver include, but are not limited to, the following:

1. Detection of focal hepatic lesions
2. Evaluation of hepatic and biliary abnormalities, including focal lesions and diffuse pathologies.
3. Evaluation for known or suspected metastases, including preoperative mapping for liver resection and locoregional treatments
4. Evaluation of vascular patency, including Budd-Chiari and portal vein thrombosis
5. Evaluation and noninvasive quantification of iron, fat, and fibrosis in chronic liver disease, such as hemochromatosis, hemosiderosis, metabolic dysfunction-associated steatotic liver disease and hepatitis in adult and pediatric patients
6. Evaluation of the cirrhotic liver and hepatocellular carcinoma (HCC) surveillance
7. Clarification of findings from other imaging studies, laboratory abnormalities, or alternative imaging for contraindications to CT scans
8. Staging of liver and biliary cancers, including assessment of vascular and biliary involvement
9. Evaluation of liver infection
10. Potential liver donor evaluation, liver resection evaluation, liver transplant evaluation, and evaluation of postsurgical complications
11. Evaluation of tumor response to treatment, for example, image-guided liver interventions/tumor ablation, chemoembolization, radioembolization, chemotherapy, immunotherapy, radiotherapy, surgery or combination treatments
12. Evaluation of known or suspected congenital abnormalities
13. Informing or guiding clinical decision making and treatment planning
14. Evaluation of biliary and vascular anatomy
15. Evaluation for biliary leak
16. Evaluation for biliary pathologies, including biliary obstruction, inflammation and infection
17. MR elastography

## **III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL**

See the [ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging \(MRI\)](#) [1].

## **IV. SPECIFICATIONS OF THE EXAMINATION**

The written or electronic request for MRI of the liver should provide sufficient information to demonstrate the medical necessity of the examination and allow for the proper performance and interpretation of the examination.

Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). The provision of additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.

The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the state scope of practice requirements. (ACR Resolution 35 adopted in 2006 – revised in 2016, Resolution 12-b)

The supervising physician must have adequate understanding of the indications, risks, and benefits of the examination as well as alternative imaging procedures. The physician must be familiar with potential hazards associated with MRI, including potential adverse reactions to contrast media. The physician should be familiar with relevant previous ancillary studies. The physician performing MRI interpretation must have a clear understanding and knowledge of the relevant anatomy and pathophysiology.

The supervising physician must also understand the pulse sequences to be used and their effect on the appearance of the images, including the potential generation of image artifacts. An understanding of the different contrast agents used for liver MRI and the basis for choosing between them is critical. Standard imaging protocols may be altered on a case-by-case basis when necessary. These protocols should be reviewed and updated periodically.

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **A. Patient Selection**

The physician responsible for the examination should supervise patient selection and preparation and be available for consultation by direct communication. Patients must be screened and interviewed prior to the examination to exclude individuals who may have contraindications to MRI, in which the risks may outweigh the benefits (see the [ACR Manual on MR Safety](#) [2]).

Certain indications require administration of intravenous (IV) contrast media. IV contrast administration should be performed using appropriate injection protocols and in accordance with the institution's policy on IV contrast utilization (see the [ACR-SPR Practice Parameter for the Use of Intravascular Contrast Media](#) [3]).

Patients suffering from anxiety or claustrophobia or who are unable to cooperate or suspend respiration, such as children, may require sedation or additional assistance to achieve a diagnostic examination. If sedation is necessary, refer to the [ACR-SIR Practice Parameter for Minimal and/or Moderate Sedation/Analgesia](#) [4] and the American Academy of Pediatrics (AAP) - American Academy of Pediatric Dentistry: Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic procedures [5].

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **B. Facility Requirements**

Appropriate emergency equipment and medications must be immediately available to treat adverse reactions associated with administered medications. The equipment and medications should be monitored for inventory and drug expiration dates on a regular basis. The equipment, medications, and other emergency support must also be appropriate for the range of ages and sizes in the patient population.

#### **IV. SPECIFICATIONS OF THE EXAMINATION**

##### **C. Examination Technique**

A phased array surface coil should be used [6] unless precluded by patient body habitus or scan indication. The field of view should be selected so that it includes the entire liver.

An adequate MRI examination of the liver is typically performed in the axial plane, and coronal plane images are added as necessary to improve the visualization of the liver dome, vasculature, and bile ducts and to facilitate interventional and surgical planning.

An adequate MRI examination of the liver should include T2-weighted imaging, which may be performed with an accelerated fast spin-echo, single-shot accelerated fast spin-echo (in axial and/or coronal planes). T2-weighted images can be obtained using a breath-hold or non-breath-hold technique. When a non-breath-hold technique is used, every effort should be made to minimize respiratory motion artifacts by using multiple signal averages and/or respiratory compensation or respiratory triggering, which could include bellows or navigator-triggered sequence. Other motion-correction strategies, including periodically rotated overlapping parallel lines, may be useful. For effective T2-weighting, an echo time (TE) between approximately 80 and 100 ms should be used at 1.5T and 70–100 ms at 3T. T2-weighted images aid in the detection of inflammation in diseased tissue and fluid-containing lesions (eg, cysts, biliary hamartoma, hemangiomas, and vascular malformations) or regions of abnormal accumulation of fluid [7]. When using a 2-D technique, the slice thickness and interslice gap in one of the planes should not exceed 8 and 2 mm, respectively. Parallel imaging with suitable phased-array coils is often used to reduce scan time and increase spatial resolution. Fat suppression techniques may be helpful to detect fluid and inflammation and to improve image contrast dynamic range.

IV contrast enhancement with gadolinium chelates is critical for accurate diagnosis of various liver pathologies [8].

IV contrast may be deferred in the following scenarios: 1) no IV access, 2) history of previous allergic-type reaction to gadolinium chelates without premedication before the study, 3) contraindication to gadolinium chelates (such as pregnancy), 4) known or suspected nephrogenic systemic fibrosis (NSF) or concerns regarding NSF risk that outweigh the benefits of a contrast-enhanced liver MR, and 5) contrast is felt unnecessary for the indication of the examination [2, 9, 10]. In patients with a high risk of NSF in whom contrast is not used, an unenhanced MR could still be helpful. A cautious risk/benefit approach is desirable with avoidance of GBCA when feasible in the pediatric population. . T1-weighted images should be acquired before gadolinium contrast injection as well as during late hepatic arterial, portal venous, and 2- to 5-minute delayed phases using a 2-D or 3-D technique [11, 12]. The 3-D techniques are strongly preferred. Methods to obtain late hepatic arterial phase include using a bolus timing technique, such as automated bolus detection algorithm or fluoroscopic triggering, or obtaining multiple consecutive arterial-phase data sets with higher temporal but lower spatial resolution. An optimal late arterial phase is characterized by the following:

- Hepatic artery and branches are fully enhanced
- Hepatic veins are not yet enhanced by antegrade flow
- Portal vein is enhanced to a lesser degree than the hepatic arteries

Additional delayed images with delays greater than 2–5 minutes may occasionally help characterize certain lesions, such as HCC, hemangiomas, and vascular malformations, or intrahepatic cholangio carcinomas [13-15]. Fat-suppressed 3-D T1-weighted gradient-echo images have quality comparable to that of conventional fat-suppressed 2-D gradient-echo images. 3-D data sets using the smallest voxel dimensions possible achieve the highest resolution practical in each axis. When using a 2-D technique, the slice thickness should not exceed 5mm.

Subtraction of unenhanced images from contrast-enhanced images may be helpful to assess for true enhancement for those lesions that are hyperintense on T1-weighted images before gadolinium administration such as T1 hyperintense nodules within cirrhotic livers and hepatic lesions following locoregional therapy. Efforts should be made to ensure that patients' respirations are suspended in an identical manner during precontrast and postcontrast dynamic phases to minimize mis registration artifacts. Employing additional techniques, such as compressed sensing, radial sampling, and parallel imaging, allows high-quality scans to be obtained during free breathing, which is especially important when imaging the pediatric population and patients who are ill, uncooperative, or hard of hearing .

Hepatobiliary phase (HBP) images are acquired when using hepatobiliary-specific contrast agents (HBCA) and are obtained approximately 15-20 minutes after the administration of gadoxetate disodium between 45 minutes and 3 hours after the administration of gadobenate dimeglumine. The HBP images depict retention of contrast within functioning hepatocytes, which can be helpful in further characterizing focal liver lesions, including focal nodular hyperplasia (FNH), hepatic adenomas and FNH-like lesions following chemotherapy [16]. HBP images can also be used to detect, characterize, and assess the extent of malignant disease [17-19]. Partially excreted HBCA in the biliary system, can help delineate biliary anatomy [20]. HBP image quality is important to assess before image interpretation. For patients without chronic liver disease, the liver parenchyma is unequivocally brighter than the intrahepatic blood vessels on the HBP images; otherwise, the HBP images are considered suboptimal. Poor enhancement of hepatic parenchyma may be seen in some patients with chronic liver disease. The use of HBCA may not be advisable in adult patients with total bilirubin of greater than 3 mg/mL or patients with severe hepatic iron deposition [20-22]. T2-weighted and diffusion-weighted images can be obtained after injection of gadoxetate disodium to improve time efficiency, and diffusion-weighted imaging (DWI) sequences may be delayed more than 5 minutes after injection. HBCAs have also been shown to be helpful in defining biliary leaks, and the ideal delay after gadoxetate disodium injection to detect bile leak has been shown to be 60-180 minutes.

In-phase and opposed phase chemical shift gradient-recalled echo T1-weighted imaging should be included for lesion characterization and for qualitative assessment of hepatic steatosis and iron overload; these sequences should be obtained before the administration of IV contrast material. Opposed phase images can be helpful to assess for signal loss from fat in fat-containing lesions, such as hepatocyte nuclear factor 1-alpha mutated hepatocellular adenomas and HCC. The opposed-phase TE must be shorter than the in-phase TE so that the effects of steatosis and iron deposition can be separated. Note that in livers with simultaneous iron overload and steatosis, a potential pitfall exists in which in-phase and opposed phase imaging may show no comparative signal loss (ie, signal loss due to steatosis on the out-of-phase image may be counterbalanced by signal loss due to iron

overload on the in-phase image). A number of techniques have been developed, tested, and validated for quantitative measurement of liver iron and fat content [23, 24]. These methods have been commercialized by many MR vendors and are available clinically for quantitative measure of liver iron and fat.

3T imaging systems have become widely available. Potential advantages of 3T systems include an increased signal-to-noise ratio (SNR) and an increased conspicuity of enhancement after the administration of a gadolinium chelate contrast agent. Potential disadvantages include decreased image contrast on T1-weighted images, increased predisposition to susceptibility artifact, increased chemical shift artifact, increased specific absorption rate, and signal inhomogeneity. The latter can be partially compensated for by the use of radiofrequency (RF) cushions and/or parallel transmit technology. In short, 3T imaging can offer substantial improvements in SNR and spatial resolution and/or decreases in imaging times, but sequence modifications are often required to maintain desired image contrast and reduce artifacts. However, in patients with large girths, including those with cirrhosis and large volume of ascites, the standing wave and dielectric artifacts seen on 3T MRI may render the study nondiagnostic, and these artifacts are much diminished on 1.5 T MRI.

DWI is commonly used for abdominal protocols [25-28]. The most common technique uses single-shot echo-planar imaging (SS-EPI). Breath-held, free breathing multiple-averaging, and respiratory-gated SS-EPI techniques can be used. Parallel imaging can be used to decrease imaging time and has been shown to result in accurate apparent diffusion coefficient (ADC) values [29]. DWI has shown promising results in detection and characterization of focal liver lesions, in evaluating treatment response within the Liver Imaging (LI) RADS treatment response algorithm in detection and staging of liver fibrosis revealing additional sites of disease in the abdomen [29]. The ability to depict areas of high cellularity can be helpful in hepatic lesion detection and in characterization in a noninvasive manner. DWI does not rely on IV gadolinium; therefore, its use is particularly attractive in patients who are unable to receive IV contrast agents. ADC maps can be generated to help differentiate between restricted diffusion and T2 shine-through. At least 2 b-values are obtained, including  $b = 20-50 \text{ s/mm}^2$  and  $b = 400 \text{ to } 1,000 \text{ s/mm}^2$ . However, overlap exists between ADC values of solid benign hepatocellular lesions, such as FNH or hepatocellular adenoma, and those of malignant lesions [26, 28, 30-34]. Thus, information provided by DWI needs to be interpreted in conjunction with lesion morphology and signal characteristics on other sequences. Moreover, ADC values are technique and scanner dependent; diagnostic cutoff values reported in the literature may not be applicable to other scanners. Techniques such as simultaneous multislice technique may allow DWI to be performed in under 1 minute [35].

MR cholangiopancreatography (MRCP) noninvasively evaluates the biliary tree. Usually, an MRCP is comprised of a series of 2-D and 3-D heavily T2-weighted sequences that maximally depict the water content in the biliary tree while suppressing signal from other tissues and, thus, optimizing visualization of biliary strictures and filling defects, such as stones, blood products, and gas. For detecting choledocholithiasis, MRCP sequences alone may be adequate. For the evaluation of malignancy, inflammatory and infectious etiologies, MRCP images may be added to a contrast-enhanced liver MRI to better evaluate for biliary wall thickening and degree of enhancement, hepatic parenchymal evaluation, and biliary and hepatic tumor evaluation [36]. The 2-D sequence is typically breath-held, thick-slab coronal acquisitions of 15-40 mm thickness with maximal coverage of the pancreaticobiliary tree and a TR 4500 ms, TE 750 ms [36, 37]. These 2-D images may be acquired in a radial fashion with 10-12 slabs rotating 360 degrees or as single coronal and 30-degree oblique images. Three-dimensional MRCP images are volumetric acquisitions of the pancreaticobiliary tree with TR 6000 ms, TE 700 ms [37]. Because of the long acquisition time of 4-6 minutes for the 3D sequence, the acquisition is free-breathing, and techniques, such as respiratory-triggering and respiratory compensation, are employed. As with other T2-weighted sequences, MRCP sequences benefit from parallel imaging to decrease acquisition time and improve image quality. The volumetric data of the 3D sequence allows for image manipulation, including the creation of maximum intensity projections and reformations into multiple planes. The 3D images also exhibit higher SNR than the 2-D images and better display subtle abnormalities of the biliary tree. On the other hand, 2-D MRCP images are less susceptible to motion and other artifact degradation than the 3-D images. If extracellular gadolinium-based IV contrast is to be administered, MRCP images may be performed before or after contrast administration. Postcontrast MRCP acquisitions benefit from gadolinium's shortened T2 relaxation time that results in improved suppression of signal from background tissues. If HBCAs are to be administered, MRCP images should be acquired before contrast administration or only shortly after administration. Because HBCA is excreted into the biliary tree, the increased gadolinium concentration within the ducts causes shortening of the

T2 relaxation time, resulting in low signal in the bile ducts. Balanced steady state-free precession MRCP may be additionally acquired as 2-D or 3-D sequences. This gradient echo sequence requires a short acquisition time, allowing for either breath-holding or respiratory-triggering, and is relatively insensitive to flow artifacts and pseudo filling defects [36].

MR elastography is a technique that enables measurement of liver stiffness. Published data over the last 5 years show that this method has high accuracy in discriminating different stages of liver fibrosis [38-42].

## **V. DOCUMENTATION**

Reporting should be in accordance with the [ACR Practice Parameter for Communication of Diagnostic Imaging Findings](#) [38].

In patients at high risk for HCC, please refer to the LI-RADS (<https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/LI-RADS>) for additional guidance on reporting of MRI in this population.

Pediatric Liver Tumors, please refer to the 2017 version of the Pediatric liver tumor staging (PRETEXT) classification system for additional guidance on reporting of MRI in this population [43].

Specific policies and procedures related to MRI safety should be in place with documentation that is updated annually and compiled under the supervision and direction of the supervising MRI physician. Guidelines should be provided that deal with potential hazards associated with MRI examination of the patient as well as to others in the immediate area [39, 44, 45]. Screening forms must also be provided to detect those patients who may be at risk for adverse events associated with the MRI examination [39, 44, 45].

Peer-reviewed literature pertaining to MR safety should be reviewed on a regular basis [4-13]

## **VI. EQUIPMENT SPECIFICATIONS**

Equipment monitoring should be in accordance with the [ACR-AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance Imaging \(MR\) Equipment](#) [46].

The MRI equipment specifications and performance must meet all state and federal requirements. The requirements include, but are not limited to, specifications of maximum static magnetic strength, maximum rate of change of magnetic field strength (dB/dt), maximum RF power deposition (specific absorption rate), and maximum acoustic noise levels.

## **VII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection Control, and Patient Education appearing under the heading *ACR Position Statement on Quality Control and Improvement, Safety, Infection Control and Patient Education* on the ACR website (<https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement>).

## **ACKNOWLEDGEMENTS**

This practice parameter was revised according to the process described under the heading *The Process for Developing ACR Practice Parameters and Technical Standards* on the ACR website (<https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards>) by the Committee on Body Imaging (Abdominal) of the Commission on Body Imaging and by the Committee on Practice Parameters – Pediatric Radiology of the Commission on Pediatric Radiology, in collaboration with the SABI, SAR, and the SPR.

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

ACR

Fung, Alice MD, Chair  
Arora, Sandeep S MBBS  
Houshmand, Sina MD  
Li, Arleen MD

SABI

Bashir, Mustafa R MD

SAR

Borhani, Amir MD  
Lee, James T MD

SPR

Cao, Joseph Y MD  
Schechter, Ann MD

Committee on Abdominal Imaging – Body Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Brook, Olga R MD, Chair  
Carucci, Laura R MD  
Fung, Alice MD  
Houshmand, Sina MD  
Liau, Joy MD, PhD  
Turner, Mary MD  
Wolf, Ellen MD  
Yeh, Benjamin MD

Arora, Sandeep S MBBS  
Fidler, Jeff L MD  
Furlan, Alessandro MD  
Kim, David H MD  
Moreno, Courtney Coursey MD  
Wasnik, Ashish P MD  
Yeghiayan, Paula MD

Committee on Practice Parameters and Technical Standards

(ACR Committee responsible for sponsoring the draft through the process)

Caplin, Drew M MD, Chair

Committee on Practice Parameters – Pediatric Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Amodio, John B MD, Chair  
Betz, Bradford W MD  
Blumfield, Einat MD  
Goldman-Yassen, Adam MD  
Lala, Shailee V MD  
Laufer, Adina MD  
Li, Arleen MD  
Noda, Sakura MD  
Trout, Andrew T MD

Alizai, Hamza MD  
Bhimaniya, Sudhir X MBBS, MD  
Collard, Michael MD  
Lai, Hollie A MD  
Lasiecka, Zofia M MD, PhD  
Levin, Terry L MD  
Maloney, John A MD  
Shah, Summit MD  
Vatsky, Seth DO

Bulas, Dorothy I MD, Chair, Commission on Pediatric Radiology

Larson, David B MBA, MD, Chair, Commission on Quality and Safety

Rosenkrantz, Andrew MD, Chair, Commission on Body Imaging

Comments Reconciliation Committee

Edmonson, Heidi A PhD - CSC, Chair  
Amodio, John B MD  
Bashir, Mustafa R MD  
Brook, Olga R MD  
Cao, Joseph Y MD  
Fung, Alice MD  
Larson, David B MBA, MD  
Li, Arleen MD  
Schechter, Ann MD

Elahi, Fatima DO, MHA - CSC, Co-Chair  
Arora, Sandeep S MBBS  
Borhani, Amir MD  
Bulas, Dorothy I MD  
Caplin, Drew M MD  
Houshmand, Sina MD  
Lee, James T MD  
Rosenkrantz, Andrew MD

## REFERENCES

1. American College of Radiology. ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging (MRI). Available at: <https://gravitas.acr.org/PPTS/GetDocumentView?docId=146+&releaseld=2>
2. American College of Radiology. ACR Committee on MR Safety. 2024 ACR Manual on MR Safety. Available at: <https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Radiology-Safety/Manual-on-MR-Safety.pdf>.
3. American College of Radiology. ACR-SPR Practice Parameter for the use of Intravascular Contrast Media. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=142+&releaseld=2>
4. American College of Radiology. ACR-SIR Practice Parameter For Minimal and/or Moderate Sedation/Analgesia. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=95+&releaseld=2>
5. CotéCharles JCJ, WilsonStephenS, AMERICAN ACADEMY OF PEDIATRICS, AMERICAN ACADEMY OF PEDIATRIC DENTISTRY. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures: Update 2016. *Pediatrics* 138, .
6. HelmbergerTTInstitut für Radiologische Diagnostik, Universität München., HolzknechtNN, LackerbauerC ACA, et al. [Phased-array superficial coil and breath holding technique in MRI of the liver. Comparison of conventional spin echo sequences with rapid fat suppressing gradient echo and turbo-spin sequences]. *Radioloe* 35:919-24, .
7. KimBong SooBSDepartment of Radiology, Jeju National University Hospital, Jeju National University School of Medicine, 1753-3, Ara-1-dong, Jeju-si, Jeju-do 690-716, Korea., AngthongWiranaWDepartment of Radiology, University of North Carolina Hospitals, University of North Carolina at Chapel Hill, CB 7510, 2001 Old Clinic Building, Chapel Hill, NC 27599-7510, USA., JeonYong-HwanYHDepartment of Radiology, University of North Carolina Hospitals, University of North Carolina at Chapel Hill, CB 7510, 2001 Old Clinic Building, Chapel Hill, NC 27599-7510, USA., SemelkaRichard CRCDepartment of Radiology, University of North Carolina Hospitals, University of North Carolina at Chapel Hill, CB 7510, 2001 Old Clinic Building, Chapel Hill, NC 27599-7510, USA.. Electronic address: richsem@med.unc.edu.. Body MR imaging: fast, efficient, and comprehensive. *Radiol Clin North Am* 52:623-36, .
8. YamashitaYYDepartment of Radiology, Kumamoto University School of Medicine, Japan., HatanakaYY, YamamotoHH, et al. Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging. *Radiology* 193:59-65, .
9. Broome DR, Gigris MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. *AJR*. 2007; 188(2):586-592.
10. American College of Radiology. ACR Committee on Drugs and Contrast Media. Manual on Contrast Media. Available at: <https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Contrast-Manual>.
11. MitchellID GDGDepartment of Radiology, Thomas Jefferson University Hospital, Philadelphia, PA 19107., PalazzoJJ, HannH WHW, RifkinM DMD, BurkD LDLJr, RubinRR. Hepatocellular tumors with high signal on T1-weighted MR images: chemical shift MR imaging and histologic correlation. *J Comput Assist Tomogr* 15:762-9, .
12. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. *Radiology*. 2001 Jan;218(1):27-38.
13. RungeV MVMDepartment of Radiology, University of Kentucky, Lexington 40536-0098, USA.. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. *J Comput Assist Tomogr* 22:643-50, .
14. SemelkaR CRCDepartment of Radiology, University of North Carolina Medical Center, Chapel Hill 27599-7510., BrownE DED, AscherS MSM, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. *Radiology* 192:401-6, .
15. SoyerPPDepartment of Radiology, Johns Hopkins Hospital, Baltimore, MD 21287, USA., BluemkeD ADA, ReichleRR, et al. Imaging of intrahepatic cholangiocarcinoma: 2. Hilar cholangiocarcinoma. *AJR Am J Roentgenol* 165:1433-6, .
16. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. *Invest Radiol* 2008; 43(7):504-511.
17. Duncan JK, Ma N, Vreugdenburg TD, Cameron AL, Maddern G. Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis. [Review]. *J Magn Reson Imaging*. 45(1):281-290, 2017 01.
18. Jhaveri KS, Fischer SE, Hosseini-Nik H, et al. Prospective comparison of gadoxetic acid-enhanced liver MRI and contrast-enhanced CT with histopathological correlation for preoperative detection of colorectal liver metastases following chemotherapy and potential impact on surgical plan. *HPB*. 19(11):992-1000, 2017 11.
19. Vilgrain V, Esvan M, Ronot M, Caumont-Prim A, Aube C, Chatellier G. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. *European Radiology*. 26(12):4595-

4615, 2016 Dec.

**20.** American College of Radiology. Hepatobiliary Agents. LI-RADS CT/MRI Manual [Available at: <https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/Chapter-13-HBA.pdf?la=en>].

**21.** Hope TA, Fowler KJ, Sirlin CB, et al. Hepatobiliary agents and their role in LI-RADS. [Review]. *Abdominal Imaging*. 40(3):613-25, 2015 Mar.

**22.** Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS). [Review]. *Journal of Magnetic Resonance Imaging*. 49(5):1236-1252, 2019 05.

**23.** Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: state of the art and remaining challenges. [Review]. *Journal of Magnetic Resonance Imaging*. 40(5):1003-21, 2014 Nov.

**24.** Kuhn JP, Hernando D, Mensel B, et al. Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. *J Magn Reson Imaging*. 39(6):1494-501, 2014 Jun.

**25.** Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. *AJR Am J Roentgenol* 2007;188:1622-35.

**26.** Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. *Radiology*. 2008;246(3):812-822.

**27.** Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. [Review] [140 refs]. *Radiology*. 254(1):47-66, 2010 Jan.

**28.** Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. *Radiology*. 2003 Jan;226(1):71-8.

**29.** Lewin M, Poujol-Robert A, Boelle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. *Hepatology*. 2007;46(3):658-665.

**30.** Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. *Eur Radiol*. 2008; 18(3):477-485.

**31.** Miller FH, Hammond N, Siddiqi AJ, et al. Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. *J Magn Reson Imaging*. 2010; 32(1):138-147.

**32.** Agnello F, Ronot M, Valla DC, Sinkus R, Van Beers BE, Vilgrain V. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. *Radiology*. 2012;262(2):511-519.

**33.** Cieszanowski A, Anysz-Grodzicka A, Szeszkowski W, et al. Characterization of focal liver lesions using quantitative techniques: comparison of apparent diffusion coefficient values and T2 relaxation times. *Eur Radiol*. 22(11):2514-24, 2012 Nov.

**34.** Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM. The value of diffusion-weighted imaging in characterizing focal liver masses. *Acad Radiol*. 2009; 16(10):1208-1214.

**35.** Taron J, Martirosian P, Erb M, et al. Simultaneous multislice diffusion-weighted MRI of the liver: Analysis of different breathing schemes in comparison to standard sequences. *Journal of Magnetic Resonance Imaging*. 44(4):865-79, 2016 10.

**36.** Welle CL, Miller FH, Yeh BM. Advances in MR Imaging of the Biliary Tract. *Magn Reson Imaging Clin N Am*. 2020 Aug;28(3):S1064-9689(20)30015-5.

**37.** Itani M, Lalwani N, Anderson MA, Arif-Tiwari H, Pasupulati RM, Shetty AS. Magnetic resonance cholangiopancreatography: pitfalls in interpretation. *Abdom Radiol (NY)*. 2023 Jan;48(1):91-105.

**38.** American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseld=2>

**39.** Colletti PM. Magnetic resonance procedures and pregnancy. In: Shellock FG, ed. *Magnetic Resonance Procedures: Health Effects and Safety*. Boca Raton, Fla.: CRC Press; 2001.

**40.** Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clin Gastroenterol Hepatol*. 2015 Mar;13(3):S1542-3565(14)01395-0.

**41.** Serai SD, Obuchowski NA, Venkatesh SK, et al. Repeatability of MR Elastography of Liver: A Meta-Analysis. *Radiology*. 2017 Oct;285(1):92-100.

**42.** Horowitz JM, Venkatesh SK, Ehman RL, et al. Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel. [Review]. *Abdom Radiol*. 42(8):2037-2053, 2017 Aug.

**43.** Towbin AJ, Meyers RL, Woodley H, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). *Pediatr Radiol*. 2018 Apr;48(4):536-554.

**44.** Shellock FG. Magnetic Resonance Procedures: Health Effects and Safety. Boca Raton, Fla.: CRC Press; 2001.

**45.** Shellock FG. Reference Manual for Magnetic Resonance Safety, Implants, and Devices. Playa Del Rey, CA: Biomedical Research Publishing Group; 2013.

**46.** American College of Radiology. ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance (MR) Imaging Equipment. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=57+&releaseId=2>

\*Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised, or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council.

Development Chronology for this Practice Parameter

2005 (Resolution 3)

Amended 2006 (Resolution 35)

Revised 2010 (Resolution 14)

Amended 2014 (Resolution 39)

Revised 2015 (Resolution 3)

Revised 2020 (Resolution 27)

Amended 2023 (Resolution 2c)

Revised 2025 (Resolution 1)